JP2011518338A - ボレリア・ブルグドルフェリ（ｂｏｒｒｅｌｉａｂｕｒｇｄｏｒｆｅｒｉ）の細胞エンベロープタンパク質のアレイ - Google Patents
ボレリア・ブルグドルフェリ（ｂｏｒｒｅｌｉａｂｕｒｇｄｏｒｆｅｒｉ）の細胞エンベロープタンパク質のアレイ Download PDFInfo
- Publication number
- JP2011518338A JP2011518338A JP2011506284A JP2011506284A JP2011518338A JP 2011518338 A JP2011518338 A JP 2011518338A JP 2011506284 A JP2011506284 A JP 2011506284A JP 2011506284 A JP2011506284 A JP 2011506284A JP 2011518338 A JP2011518338 A JP 2011518338A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- proteins
- cell envelope
- test sample
- microarray
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101710091045 Envelope protein Proteins 0.000 title claims abstract description 50
- 101710188315 Protein X Proteins 0.000 title claims abstract description 50
- 102100021696 Syncytin-1 Human genes 0.000 title claims abstract description 50
- 241000589969 Borreliella burgdorferi Species 0.000 title claims abstract description 34
- 238000000034 method Methods 0.000 claims abstract description 41
- 208000016604 Lyme disease Diseases 0.000 claims abstract description 36
- 238000002493 microarray Methods 0.000 claims abstract description 35
- 108090000623 proteins and genes Proteins 0.000 claims description 89
- 102000004169 proteins and genes Human genes 0.000 claims description 84
- 238000012360 testing method Methods 0.000 claims description 27
- 108700026244 Open Reading Frames Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 description 45
- 210000002966 serum Anatomy 0.000 description 29
- 239000000427 antigen Substances 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 108700023315 OspC Proteins 0.000 description 10
- 241000589968 Borrelia Species 0.000 description 8
- 108010052285 Membrane Proteins Proteins 0.000 description 8
- 102000018697 Membrane Proteins Human genes 0.000 description 8
- 108090001030 Lipoproteins Proteins 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 102000004895 Lipoproteins Human genes 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 206010061591 Borrelia infection Diseases 0.000 description 3
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 241000589970 Spirochaetales Species 0.000 description 3
- 235000011941 Tilia x europaea Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000004571 lime Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000003498 protein array Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 101100165567 Borrelia bavariensis (strain ATCC BAA-2496 / DSM 23469 / PBi) bmpA2 gene Proteins 0.000 description 1
- 241000276440 Borrelia burgdorferi B31 Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 229940124073 Complement inhibitor Drugs 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 102100035784 Decorin Human genes 0.000 description 1
- 108090000738 Decorin Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 241000238681 Ixodes Species 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 208000008551 Lyme Neuroborreliosis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108700006640 OspA Proteins 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 101100431670 Rattus norvegicus Ybx3 gene Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- YVNQAIFQFWTPLQ-UHFFFAOYSA-O [4-[[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfophenyl)methyl]amino]-2-methylphenyl]methylidene]-3-methylcyclohexa-2,5-dien-1-ylidene]-ethyl-[(3-sulfophenyl)methyl]azanium Chemical compound C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=C1 YVNQAIFQFWTPLQ-UHFFFAOYSA-O 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 101150014900 bmpA gene Proteins 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000004074 complement inhibitor Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 101150025819 erp gene Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000011410 subtraction method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/20—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12504008P | 2008-04-22 | 2008-04-22 | |
| US61/125,040 | 2008-04-22 | ||
| PCT/US2009/002474 WO2009131665A1 (en) | 2008-04-22 | 2009-04-21 | Borrelia burgdorferi cell envelope protein array |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011518338A true JP2011518338A (ja) | 2011-06-23 |
| JP2011518338A5 JP2011518338A5 (enExample) | 2012-06-07 |
Family
ID=40933495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011506284A Pending JP2011518338A (ja) | 2008-04-22 | 2009-04-21 | ボレリア・ブルグドルフェリ（ｂｏｒｒｅｌｉａｂｕｒｇｄｏｒｆｅｒｉ）の細胞エンベロープタンパク質のアレイ |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20110105355A1 (enExample) |
| EP (1) | EP2274616A1 (enExample) |
| JP (1) | JP2011518338A (enExample) |
| WO (1) | WO2009131665A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018536429A (ja) * | 2015-09-25 | 2018-12-13 | キアゲン サイエンシス リミテッド ライアビリティ カンパニー | ライム病を診断するためのおよび治療後のライム病スピロヘータ除去を予測するための組成物および方法 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110105355A1 (en) * | 2008-04-22 | 2011-05-05 | Research Foundation Of State University Of New York | Borrelia burgdorferi cell envelope protein array |
| WO2011143617A1 (en) | 2010-05-14 | 2011-11-17 | Baxter International Inc. | Chimeric ospa genes, proteins, and methods of use thereof |
| CA2812759A1 (en) | 2010-09-27 | 2012-04-12 | Cornell University | Methods for diagnosing lyme disease |
| CN104640563A (zh) | 2012-07-27 | 2015-05-20 | 巴克斯特国际公司 | 包含嵌合的ospa分子的组合物及其使用方法 |
| US11061028B2 (en) | 2014-09-24 | 2021-07-13 | Defined Diagnostics, Llc | Compositions and methods for the diagnosis of lyme disease |
| WO2018017998A1 (en) | 2016-07-22 | 2018-01-25 | The Research Foundation For The State University Of New York | Recombinant borrelia proteins and methods of use thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01259258A (ja) * | 1988-04-08 | 1989-10-16 | Tokuyama Soda Co Ltd | ライム病抗体検出用凝集反応試薬 |
| JPH072696A (ja) * | 1991-07-11 | 1995-01-06 | Immuno Ag | ライム病を予防するための方法及び組成物 |
| JP2001516458A (ja) * | 1998-01-08 | 2001-09-25 | ビオメリュー インコーポレイテッド | 診断試薬としての組換えＰ３７／ＦｌａＡ |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6248562B1 (en) | 1993-11-01 | 2001-06-19 | Research Foundation State University Of New York | Chimeric proteins comprising borrelia polypeptides and uses therefor |
| US7008625B2 (en) | 1993-11-01 | 2006-03-07 | Research Foundation Of The State University Of New York | Recombinant constructs of Borrelia burgdorferi |
| US6251405B1 (en) | 1995-06-07 | 2001-06-26 | Connaught Laboratories, Inc. | Immunological combination compositions and methods |
| DE60030859T2 (de) | 1999-06-18 | 2007-06-14 | The Research Foundation Of State University Of New York | Gruppen von borrelia burgdorferi, die lyme krankheit verursachen |
| EP2292762A3 (en) * | 2002-12-20 | 2012-12-12 | Board of Regents, The University of Texas System | VMP-like sequences of pathogenic Borrelia species and strains |
| US8129165B2 (en) * | 2006-09-15 | 2012-03-06 | Intercell Ag | Borrelia antigens |
| EP2191266A4 (en) * | 2007-09-07 | 2011-08-03 | Univ California | BORRELIA DIAGNOSTIC AND SCREENING METHOD |
| US20110105355A1 (en) * | 2008-04-22 | 2011-05-05 | Research Foundation Of State University Of New York | Borrelia burgdorferi cell envelope protein array |
-
2009
- 2009-04-21 US US12/989,003 patent/US20110105355A1/en not_active Abandoned
- 2009-04-21 WO PCT/US2009/002474 patent/WO2009131665A1/en not_active Ceased
- 2009-04-21 JP JP2011506284A patent/JP2011518338A/ja active Pending
- 2009-04-21 EP EP09733687A patent/EP2274616A1/en not_active Withdrawn
-
2010
- 2010-05-21 US US12/784,584 patent/US20100292096A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01259258A (ja) * | 1988-04-08 | 1989-10-16 | Tokuyama Soda Co Ltd | ライム病抗体検出用凝集反応試薬 |
| JPH072696A (ja) * | 1991-07-11 | 1995-01-06 | Immuno Ag | ライム病を予防するための方法及び組成物 |
| JP2001516458A (ja) * | 1998-01-08 | 2001-09-25 | ビオメリュー インコーポレイテッド | 診断試薬としての組換えＰ３７／ＦｌａＡ |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018536429A (ja) * | 2015-09-25 | 2018-12-13 | キアゲン サイエンシス リミテッド ライアビリティ カンパニー | ライム病を診断するためのおよび治療後のライム病スピロヘータ除去を予測するための組成物および方法 |
| US10983121B2 (en) | 2015-09-25 | 2021-04-20 | Qiagen Sciences Llc | Compositions and methods for diagnosing Lyme disease and for predicting Lyme disease spirochete elimination after treatment |
| US12066436B2 (en) | 2015-09-25 | 2024-08-20 | Qiagen Sciences Llc | Compositions and methods for diagnosing Lyme disease and for predicting Lyme disease spirochete elimination after treatment |
Also Published As
| Publication number | Publication date |
|---|---|
| US20100292096A1 (en) | 2010-11-18 |
| WO2009131665A1 (en) | 2009-10-29 |
| US20110105355A1 (en) | 2011-05-05 |
| EP2274616A1 (en) | 2011-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7598843B2 (ja) | 腎疾患及び歯周疾患を検出及び診断するための方法及び組成物 | |
| JP2011518338A (ja) | ボレリア・ブルグドルフェリ（ｂｏｒｒｅｌｉａｂｕｒｇｄｏｒｆｅｒｉ）の細胞エンベロープタンパク質のアレイ | |
| Xu et al. | Profiling the humoral immune response to Borrelia burgdorferi infection with protein microarrays | |
| JP2017531657A (ja) | 組換えボレリアタンパク質およびその使用のための方法 | |
| HUE034632T2 (en) | Improved vaccine diagnostics | |
| RU2549698C2 (ru) | Химерный белок боррелии, нуклеиновая кислота, кодирующая такой белок, экспрессирующая кассета, вектор, способ и набор для диагностики лайм-боррелиоза, вакцина для профилактики боррелиоза | |
| US20200348300A1 (en) | Mycobacterium avium subspecies paratuberculosis immunodiagnostic antigens, methods, and kits comprising same | |
| US8163500B2 (en) | Polypeptides and methods for the specific detection of antibodies in patients with a Borrelia infection | |
| WO2024050512A2 (en) | Use of immunogenic t cell epitopes for lyme disease vaccination and diagnosis | |
| FI112544B (fi) | Menetelmä varhais- ja myöhäisvaiheen Lymen borrelioosin diagnosoimiseksi | |
| RU2546246C2 (ru) | Химерный белок, используемый для диагностики лайм-боррелиоза. | |
| US20040142399A1 (en) | Recombinant FlaA as a diagnostic reagent | |
| US20170212114A1 (en) | Recombinant Borrelia Proteins And Methods Of Use Thereof | |
| US11899015B1 (en) | Chimeric recombinant proteins and recombinant protein panels for the diagnosis of Lyme disease in animals and humans | |
| DK2396655T4 (en) | Device for serologically detecting yersinia infections and / or their sequelae, and using the proteins MyfA and PsaA of Y.Enterocolitica and Y.Pseudotuberculosis as recombinant antigens | |
| US20250101086A1 (en) | Monoclonal antibody specific for ir4 or ir6 peptides | |
| WO2018017998A1 (en) | Recombinant borrelia proteins and methods of use thereof | |
| CA2634638C (en) | A bioassay and peptides for use therein | |
| EP4608438A1 (en) | Chimeric recombinant proteins and recombinant protein panels for the diagnosis of lyme disease in animals and humans | |
| EP2024497A2 (en) | Liga and ligb proteins (leptospiral ig-like (lig) domains) for vaccination and diagnosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120417 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120417 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20121030 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121102 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130131 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130304 |